Highest-materiality recent filing
Ainos FY2025 revenue up 499%, gross margin 82.9%; AI Nose deployments scaling in semiconductor
Revenue up ~499% YoY; gross margin improved to 82.9% from a gross loss in 2024.
Ainos Q3 2025 results omit financials; focuses on AI Nose partnerships and patents
No net revenue or EPS disclosed in Q3 2025 press release; SG&A down 22% YoY, total opex down 8%.
Ainos Q2 2025 results highlight $2.1M AI Nose order and commercial momentum
Secured $2.1M three-year subscription order from ASEH for AI Nose in semiconductor manufacturing.
Ainos secures $2.1M order with ASE for AI Nose deployment in semiconductor manufacturing
Three-year subscription order valued at $2.1M from ASE Technology Holding, the world's largest semiconductor assembly and test provider.
Ainos regains Nasdaq compliance; sets 90-day AI Nose scale plan with 412% Q1 revenue jump
Nasdaq confirmed compliance on July 15, 2025; closing bid price >= $1.00 for 10 consecutive days.
Ainos forms strategic partnership with Kenmec to deploy AI Nose in smart factories
Legally binding strategic partnership announced June 24, 2025.
Revenue up 412% YoY to $106,207; gross profit of $87,974 vs prior-year gross loss of $6,025.
Ainos signs MOU with ASE to deploy AI Nose for semiconductor VOC detection
Ainos (AIMD) and Advanced Semiconductor Engineering (ASE) signed a legally binding MOU to integrate AI Nose into ASE's 46 fully automated factories.
Ainos reports FY2024 revenue $20,729, net loss $14.9M; AI Nose and VELDONA progress
Revenue fell 83% YoY to $20,729; cost of revenues $52,595; gross loss narrowed to $31,866.
Ainos partners with ugo to integrate AI Nose into robots for scent detection
Ainos (AIMD) and ugo, Japan's largest service robot firm, to develop first smell-enabled robot.
Ainos signs non-binding MOU with Taiwan Tanabe for VELDONA manufacturing and Taiwan market
Non-binding MOU with Taiwan Tanabe Seiyaku (Mitsubishi Tanabe subsidiary) for exclusive marketing, manufacturing, and marketing authorization of VELDONA in Taiwan.
Issued 5.5M shares to TCNT for exclusive, irrevocable, perpetual license of gas-sensor and medical-device patents.
Ainos receives Nasdaq deficiency notice for bid price below $1; 180 days to cure
Nasdaq notified Ainos that its common stock bid price closed below $1.00 for 30 consecutive business days.
Clinical trials for AI Nose-powered Ainos Flora achieved 75 meaningful case results, validating AI algorithm model.
Ainos Q1 revenue down 58% YoY to $20.7K; net loss widens to $3.3M; secures $9M convertible note
Revenue of $20,729 in Q1 2024, down 58% from $49,164 in Q1 2023, due to pivot from COVID-19 test kits.
Ainos issues $9M convertible note to ASE Test, with warrant for 500k shares
$9,000,000 convertible note, 6% compound interest, matures May 3, 2027.
Ainos reports FY2023 revenue drop to $122K; net loss $13.8M
Revenue fell 97% to $122,112 from $3.52M in 2022, driven by COVID-19 test kit sales decline.
Ainos submits clinical hold complete response to FDA for VELDONA Phase 2 COVID-19 trial
Submitted clinical hold complete response to FDA for Phase 2 trial of low-dose oral IFN-alpha VELDONA for mild COVID-19.
Ainos secures $1.75M additional funding via amended convertible note with Lind Global
$1.75M total, $875k funded at closing; $875k subject to registration statement conditions.
Reverse stock split at 1-for-5 ratio effective Dec 14, 2023; fractional shares paid in cash.
Ainos issues 3,000,000 shares of common stock as Special Stock Awards to officers and directors
3M shares issued unregistered under Section 4(a)(2)/Reg D to nine insiders.
Ainos Q3 2023 revenue drops 98.6% to $24.5K; net loss narrows to $3.0M
Revenue fell to $24,489 from $1,757,774 in Q3 2022 due to COVID-19 test kit demand decline.
Ainos enters $10M private placement with Lind Global; initial $3M tranche funded
Initial closing: $2M funded now; remaining $1M subject to shareholder approval and SEC registration.
Ainos Q2 revenue collapses to $28.6K; net loss widens to $2.35M
Revenue dropped ~95% YoY to $28,555 from $636,627 due to COVID slowdown in Taiwan.
As of August 9, 2024, Lawrence K. Lin transitioned from his role as the Company’s Executive Vice President of Operations, effective August 9, 2024.
On March 15, 2024, the Board of Directors appointed Christopher Hsin-Liang Lee as the Chief Financial Officer of Ainos, Inc. (the “Company”).
On March 13, 2024, Meng-Lin Sung, the Chief Financial Officer of Ainos, Inc. (the “Company”), resigned from her positions with the Company, effective as of such date.
On May 17, 2023, the Board of Directors appointed Meng-Lin Sung (Amanda) as the Chief Financial Officer of the Company.
On May 16, 2023, Ms. Hui-Lan (Celia) Wu retired as the CFO of the Company.
On June 15, 2022, the Board appointed Pao-Sheng Wei to the Board, the Compensation Committee, and the Audit Committee and as Chairman of the Audit Committee and as an Audit Committee Financial Expert.
On June 15, 2022, the Board accepted the resignation of Hsiu-Chen Chiu from the Board, the Compensation Committee, the Audit Committee and as Audit Committee Chairperson.
On June 15, 2022, the Board appointed Pao-Sheng Wei to the Board, the Compensation Committee and as Chairman of the Compensation Committee, and the Audit Committee and as Chairman of the Audit Committee and as an Audit Committee Financial Expert.
On June 15, 2022, the Board accepted the resignation of Hsiu-Chen Chiu from the Board, the Compensation Committee and as Chairperson of the Compensation Committee, and the Audit Committee and as Audit Committee Chairperson.
Mr. John Junyong Lee, Esq. age 54, was re-appointed as Chief Legal Counsel and Corporate Secretary of the Company.
Mr. Chun-Hsien Tsai resigned as Chief Financial Officer (CFO) and the vacancy was filled by the election of his successor, Ms. Hui-Lan (Celia) Wu.
Mr. Lawrence K. Lin, age 51, was elected to serve as Executive Vice President of Operations of the Company.
Max materiality 0.75 · Median 0.55 · Most common event other_material